A prospect of prolonged lockdowns seemed to cast a long shadow over the global economy. Markets took a break from this grim reality due to US elections but just when it was set to return the Pfizer/BionTech vaccine news arrived. Just like unexpected Christmas gift it caused a sheer euphoria on the markets although no everyone is happy. In this analysis we describe key facts and explain market repercussions.
Pfizer/BionTech vaccine – what do we know?
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appIt’s not the first vaccine news but it’s certainly the most concrete. Pfizer/BionTech shared results of the 3rd (key) stage of the trial and it seem nearly too good to be true. The key facts are:
- Over 90% effectiveness in preventing covid transfer
- No side effects
- 50 million doses already in 2020, 1.3 billion (!) in 2021
If that’s accurate it can really be the game changer. Markets hoped there will be vaccine at the end of this year but not so effective and so accessible.
What does it mean? (and what it does not)
It’s easy to say what this vaccine will NOT do – it will do little to ease present problems in Europe and increasingly in the US. The pandemic is spreading now and lockdowns (with associated economic costs) might be necessary to contain the situation until vaccination is broad enough. In fact, given a prospect of successful vaccine, lock-down in a near-term are actually MORE likely.
The vaccine promise is mostly about the future. It raises a hope that pandemic can be gone at some point next year and economic activity might return. The economies that were able to withstand the second COVID wave can now hope to insure themselves but from the market reaction perspective it’s those troubled ones that offer most “upside”.
Winners
Old economy that was suffering from lockdowns and insolvency fears. Oil&gas, brick&mortar commerce, traditional financials – these heavy hit markets are suddenly in favour. The most battered economies have most to gain from vaccine. SPA35 and FRA40 were gaining nearly 8% on Monday, US2000 (more mid-sized businesses, less techs) had to be stopped by a circuit breaker. OIL.WTI exploded by 10% on demand recovery hopes. On the FX front reactions are smaller but emerging market currencies (BRL, ZAR, PLN) were gaining as capital outflow from tech stocks can prefer relatively cheaper markets. On the individual stocks level cinemas, airlines and tour operators have seen the sharpest positive reaction (examples: CINE.UK, RBW.PL, AF.FR, IAG.ES).
Old economy is suddenly back in favour: OIL, European indices, EM currencies surge as Gold and yen decline on vaccine news. Source: xStation5
Losers
Not everyone is happy. So called “pandemic winners” are suddenly out of favour. On the indices level it’s most evident on tech-heavy US100: less business to be taken over from the traditional economy and rise in bond yields as a negative factor. Gold and silver are also down as safe-havens and amid prospects of higher market interest rates. JPY and CHF – again safe havens – are losing out on the FX front. Among individual stocks examples include “covid” stocks (IGN.PL), stay-at-home stocks (DHER.DE) or e-commerce (SHOP.US).
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
